In summary, this paper describes the use of an effective adjuvant mouse model of pancreatic cancer developed in our laboratory [15] to demonstrate, for the first time, that combined HGF/c-Met inhibition is effective in retarding the rate of progression of disease after surgical resection of the primary tumour. This evidence concerns the gene MET and pancreatic neoplasm.